It is a pleasure to serve under your chairmanship, Sir Charles. I thank the hon. Member for City of Chester (Christian Matheson) for securing this debate on this important issue and the hon. Member for Dagenham and Rainham (Jon Cruddas) for his comments. In my short few months in this role, we have already talked about this important topic on a number of occasions. I take it very seriously and I appreciate the tone in which this debate is taking place. Allergies affect around 20 million people in the UK. Investing in research is a key component in supporting people living with allergies. The Department of Health and Social Care funds research through the National Institute for Health Research (NIHR). In the past five years, over £14.1 million has been provided to NIHR for allergy research. Additionally, 79 studies related to allergies have been supported by the NIHR clinical research network in the last five years alone. New treatments such as Palforzia for peanut allergies are being introduced, with up to 600 children aged four to 17 expected to benefit this year and potentially rising to 2,000 in 2023. The Government recognise the challenges faced by people with allergies and are committed to ensuring that all children and adults living with allergies are well supported. They are also taking steps to protect those with allergies through initiatives like Natasha's law, which mandates full ingredient and allergen labelling for pre-packed foods sold directly to consumers. Furthermore, the Food Standards Agency (FSA) is undertaking a programme of work to improve quality of life for people living with food hypersensitivity, while the Medicines and Healthcare products Regulatory Agency plans next steps to support wider availability of adrenalin auto-injectors in public spaces.